#SkylarkBio #genetherapy #hearingloss #GJB2mediatedhearingloss #GJB2 #sensorineuralhearingloss #SNHL #GJB2relatedhearingloss #SONIXclinicaltrial #openlabelstudy #intracochlearinjection #SKYCATdevice #ForgeBiologics #AAVvector #SKYPEN #pendrinrelatedhearingloss #SLC26A4gene
zurl.co/jp426
zurl.co/jp426
Skylark trials gene therapy for common form of child deafness
Skylark Bio dosed the first patient in a phase 1/2 trial of SKY-GJB2, a gene therapy for the most common form of genetic deafness in children.
zurl.co
September 7, 2026 at 9:50 AM